A stock that lost 4.33% in a single session thirteen trading days ago just closed at a new all-time high — and did so as the highest-turnover name on the Dhaka Stock Exchange. ASIATICLAB settled at Tk 117.30 on Tuesday, up Tk 7.20, on 2.39 million shares worth an estimated Tk 274 million. No other stock on the DSE traded more by value.
The price is the part that should hold your attention. Tk 117.30 is not just a new high. It is Tk 6.50 above where the May 5 rally peaked before the May 6 crash erased it. The full round trip — rally, crash, recovery — is complete. And the pharma peers that should have moved with it did not move at all.
That second sentence is the one that matters. Here is why.
The Round Trip in Three Sessions
Three dates tell the whole story. May 5: ASIATICLAB rallies 2.88% to Tk 110.80 on volume of nearly 2 million shares. May 6: the stock crashes 4.33% to Tk 106.00, wiping out the previous day’s gain and then some. May 19: ASIATICLAB closes at Tk 117.30 — Tk 6.50 above the May 5 peak — on the heaviest volume in either direction.
The recovery did not take a week of news flow. It took nine trading sessions of grinding gains: +1.84%, +0.38%, +1.89%, +1.86%, +2.49%, then Tuesday’s +6.54% blowoff. From the May 6 close, the stock has now returned 10.66%. From its 52-week low of Tk 30.20, it has returned 296%. The annual chart is vertical.
When a stock crashes 4.33% on Tk 938 million in panic-style volume and then recovers fully on grinding accumulation, what you are looking at is not investors changing their mind. It is the same investors waiting for the dust to settle before resuming the position. That is a trading signature.
Tk 274 Million in a Stock With No News
ASIATICLAB’s turnover on Tuesday was Tk 274 million. By way of context, that single name represented a significant share of DSE activity on a session where the broader index has been declining. DSEX closed Monday at 5,203.11 — down 1.22% over the prior nine sessions, with Fitch’s negative outlook and NBFI liquidation overhang keeping buyers on the sidelines.
The 2.39 million shares that changed hands represented 63% above the stock’s 30-day average volume. There was no earnings release. There was no dividend announcement. There was no regulatory disclosure. ASIATICLAB’s FY2025 earnings actually fell 8.30% year-on-year — the most recent fundamental data point is negative. And yet 2% of the entire 122-million-share float traded in a single session at a new record price.
That is the kind of activity that does not appear on a chart by accident. Volume on no-news days is a tell.
Pharma Peers Refused to Confirm
The cleanest evidence that Tuesday’s move was not sector rotation comes from looking sideways. While ASIATICLAB jumped 6.54%, SQURPHARMA closed -0.14%. BXPHARMA finished +0.34%. RENATA fell 0.29%. BEACONPHAR slipped 0.20%. ACMELAB shed 0.13%. IBNSINA dropped 0.16%. AMBEEPHA lost 1.49%.
Eight of the largest pharmaceutical stocks on the exchange traded flat or slightly negative on the day ASIATICLAB ran 6.54% on record turnover. If the rally was driven by sector news — favourable regulation, raw material cost relief, export contract optimism — at least one of those names would have caught a bid. None did.
The pharmaceutical sector did not rally. ASIATICLAB rallied. That distinction is the whole reason this article exists.
What 35x Earnings Buys You
The stock now trades at a P/E ratio of 35.64 on trailing EPS of Tk 3.09. Square Pharmaceuticals — the dominant pharma name on the exchange — trades at a market cap roughly 40 times larger than Asiatic Laboratories. ASIATICLAB’s market capitalisation of Tk 1,348 crore now reflects expectations that revenue growth of 52.2% year-on-year continues, that FY2025’s 8.30% earnings decline reverses, and that the dividend yield of 0.90% improves.
Each of those expectations is a possibility, not a certainty. The chart is pricing them as if they are certainties.
The Whipsaw Is the Trade
Step back from the chart and the pattern becomes legible. Rally days bring in retail momentum chasers. Crash days flush them out. Grinding recoveries on lower volume allow positioned traders to accumulate at lower prices. New highs on heavy volume distribute the position to the next round of momentum chasers.
The May 5 rally, May 6 crash, and May 19 breakout are not three separate events. They are one event with three phases. ASIATICLAB is small enough to move, liquid enough to trade, and visible enough to attract retail attention every time it prints a new high. The whipsaw is not a bug in the price action. It is the entire trading strategy.
Investors looking for a fundamental thesis are bringing the wrong tools. The trade you are watching is not about the company. It is about the float.
Tuesday’s 6.54% gain on Tk 274 million in turnover does not invalidate that pattern. It completes it. And the next phase of the same loop — the one that begins with another sharp reversal — is the only part of the story that has not yet printed.